Essential Amino Acids and Parkinsons Disease (EAAPD)

University of Arkansas

Status and phase: Begins enrollment in 1 month; Phase 1

Conditions: Parkinson Disease

Treatments: Drug: Placebo; Drug: AMS2434 (amino acids)

Study type: Interventional

Funder types: Other

Identifiers

NCT06604065

EAAPD1

Details and patient eligibility

About

Parkinson's disease is a neuromuscular disease that is relatively common in elderly that has many potentials symptoms, including a variety of physical features that together reduce quality of life. The Study Team have developed a nutritional supplement (AMS2434) based on essential amino acids that targets improving muscle health and brain neurotransmitter balance. This protocol will determine in individuals with PD the effect of AMS2434 on muscle protein synthesis, neurotransmitter production, and mood and cognition.

Full description

Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra and is the second most common neurodegenerative disease in older individuals. PD may involve a variety of symptoms, but the predominant manifestation is impaired physical function, including muscle atrophy and weakness, bradykinesia, and reduced endurance. Older PD patients frequently present with, or develop, greater loss of muscle mass than expected from aging alone (sarcopenia). Sarcopenia results in inactivity, chronic inflammation, and neurodegeneration, all of which compound the loss of muscle function due to PD. L-DOPA/carbidopa is the most common drug therapy for PD and can mitigate some of the physical problems with PD, but progression of the disease usually ultimately results in severe reduction of quality of life.

The metabolic basis for loss of muscle mass with sarcopenia is anabolic resistance, defined as a diminished stimulation of muscle protein synthesis by dietary protein. Reduced muscle protein synthesis in response to dietary protein consumption not only contributes to the loss of muscle mass, but also to impaired single muscle fiber function, decreased mitochondrial biogenesis, and reduced neuromuscular junction stability, all of which contribute to impaired physical function. The consequences of anabolic resistance of muscle protein in PD is often compounded by the recommendation for reduced consumption of dietary protein due to the potential interference of absorbed dietary amino acids with the transport of L-DOPA from the intestine into the blood and from the blood into the brain.

We have developed an EAA-based nutritional supplement called AMS2434 designed to stimulate muscle protein synthesis in older individuals with PD and to promote dopamine production in the brain. AMS2434 is cleared rapidly from the blood after consumption, thereby minimally interfering with the transport of L-DOPA/carbidopa. In addition, AMS2434 contains tyrosine to enhance the brain production of dopamine. AMS2434 also decreases plasma tryptophan, which in turn reduces its degradation product kynurenine, which may be involved in the development of sarcopenia. We have previously shown that a 10g dose of EAAs maximally stimulates muscle protein synthesis in healthy elderly. In the current protocol we will determine if 10g of a mixture of a specifically designed mixture of EAAs (AMS2434) will robustly stimulate muscle protein synthesis in anabolic resistant individuals with Parkinson's disease. In addition, we will determine if AMS2434 stimulates brain dopamine synthesis from tyrosine.

Enrollment: 15 estimated patients

Sex: All

Ages: 55 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 55 years or older
• Clinical diagnosis of idiopathic Parkinson Disease
• Hoehn and Yahr stage 2-3
• Stable medication regimen with L-DOPA/carbidopa for at least 4 weeks prior to study entry

Exclusion criteria

• Findings suggestive of atypical or secondary Parkinsonism, including cerebellar sign
• Use of anticoagulation drugs (including aspirin and Plavix) within one week of the protocol
• Allergy to lidocaine
• Supranuclear gaze palsy, apraxia, prominent autonomic failure, or other cortical signs
• Multiple strokes with stepwise progression of symptoms
• Neuroleptic treatment at time of study entry or time of onset of Parkinsonism
• Inability to walk without a cane or walker
• Deep brain stimulation
• Montreal Cognitive Assessment (MoCA) score <18
• Use of investigational drugs
• Early Alzheimer's disease
• Frontotemporal dementia of dementia with Lewy bodies
• Major depression treated with SSRIs
• Individuals with auditory or visual hallucinations
• Individuals taking drugs that cause Parkinsonism like symptoms such as antipsychotics, anti-emetics, prokinectic and anti-seizure medications

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

15 participants in 2 patient groups, including a placebo group

AMS2434 (amino acids)

Experimental group

Description:

Product AMS2434. A single dose providing 10g of essential amino acids (EAAs). Study products will be in powder form and packaged in individual serving sizes and will be dissolved in 8 oz water for consumption.

Treatment:

Drug: AMS2434 (amino acids)

Placebo

Placebo Comparator group

Description:

Matched non-caloric placebo. Study products will be in powder form and packaged in individual serving sizes and will be dissolved in 8 oz water for consumption.

Treatment:

Drug: Placebo